Hillstream BioPharma is a development stage company focused on rare cancers.  By harnessing a weakness in tumors to preferentially concentrate Hillstream’s proprietary QuatramerTM technology, we are developing targeted cancer therapies.  The Company is advancing lead candidates, including novel small molecules and proprietary DNA expression vectors which encode inflammatory cytokines directly into the tumor’s genome.  We will work to improve the lives of patients as we rapidly move into the clinic to treat small cell lung cancer, soft-tissue sarcomas and other high unmet need rare cancers.

Team Members

Mr. Milby was the former Chief Executive Officer and Member of the Board of Directors at CorMedix, a publicly traded biopharmaceutical company focused on developing and commercializing therapeutic products for the prevention and treatment of inflammatory and infectious diseases. A seasoned executive who led the increase in market capitalization from $3M to a peak of $350M of Cormedix while improving the company’s financial position with capital raises from equity markets.  He oversaw efforts to gain CE Market approval of Neutrolin® in the European Union and held increasing roles of responsibility at Goldman Sachs and Dupont Merck prior in his career.

Dr. Wallin has developed drugs across multiple therapeutic areas, both small molecules and biologics. He has demonstrated proven technical and management skills in small and large pharmaceutical companies with a track record of innovative success in bringing drugs to market quickly and efficiently. He directed as well as assisted in the early clinical development (Phases 1 & 2) of several monoclonal antibodies for the treatment of mesothelioma, non-small cell lung cancer (NSCLC), ovarian cancer, pancreatic cancer, and for the treatment of rheumatoid arthritis at Morphotek, Inc.  Dr. Wallin was involved in the early clinical development of NE-180 (GlycoPEGylated recombinant human erythropoietin) and GlycoPEG-Granulocyte Colony Stimulating factor (GCSF) at Neose Technologies Inc and has had roles in clinical development and research at Adolor, Abbott and Smithkline Beecham (GSK).

Dr. Rosenblatt is a subject matter expert in the chemistry and manufacturing controls (CMC) of bio-therapeutics, with a proven 30-plus year track record in biotechnology and the pharmaceutical industry. He developed, transferred, and validated purification processes for multiple new molecular entities through all stages of drug development, including licensure by the application of an innovative and comprehensive approach. He is experienced in regulatory and technical support for non-traditional biologics and combined medical/biological devices.  Dr. Rosenblatt was responsible for a pharmaceutical development group at Centocor/Johnson & Johnson that developed processes that led to the commercial approval of two biologic candidates, Stelara® and Simponi®.

Dr. Niecestro is the Managing Director of AccelaPHARM, LLC, an executive regulatory-development strategy company in the biotechnology and pharmaceutical industries.  Dr. Niecestro was a founder and served as the Vice President of Clinical and Regulatory Affairs for Axsome Therapeutics as well as was a founder and served as the Executive Vice President of Clinical and Regulatory Affairs for TG Therapeutics and Keryx Biopharmaceuticals.  Dr. Niecestro held numerous senior management positions in the pharmaceutical industry serving as the Vice President of Clinical Development for Andrx Laboratories; Senior Director, Clinical Development and Therapeutic Head for Gastrointestinal, Oncology and Stroke at Eisai Inc.; and Director, Clinical Operations and NDA Planning for Organon Inc. Dr. Niecestro has been involved in the filing of over 60 INDs; approval of 13 NDAs or BLAs in the United States; has over 60 peer-reviewed scientific presentations, abstracts and/or publications, and holds 3 patents. Dr. Niecestro completed his graduate and post-graduate work at the University of Illinois at Chicago.

Dr. Korczak is a translational science executive with established track record of developing drugs from discovery through IND and into clinical Proof of Concept (POC) studies. She has an excellent knowledge of drug discovery, pharmacology, pharmacokinetics (PK), toxicology, manufacturing of drug substance/product, early clinical development and regulatory requirements. Her leadership in start-up and early stage biotechnology companies resulted in accelerated  drug development across multiple therapeutic areas including oncology, dermatology, inflammatory diseases, cardiology, and infectious diseases.

Scientific Advisory Board Members

Dr. Kufe is a Distinguished Physician at Dana-Farber Cancer Institute (DCFI) and Professor of Medicine at Harvard Medical School.  Over the past 30 years, he has served as Chief of the Division of Cancer Pharmacology, Deputy Director of the Dana-Farber Cancer Center, Director of the Harvard Phase I Oncology Group and Leader of the Developmental Therapeutics Program in the Dana-Farber/Harvard Cancer Center. Dr. Kufe has focused his career on the preclinical and clinical development of anti-cancer agents, including targeted drugs, monoclonal antibodies and cancer vaccines, the latter of which are now under evaluation in two multi-center national trials.

Dr. Wong is the Chief of Hematology and Medical Oncology at The Perlmutter Cancer Center at NYU Langone Medical Center. During his distinguished career, Dr. Wong served in various investigative and leadership roles at Dana-Farber Cancer Institute, Brigham & Women’s Hospital, and Harvard Medical School. His work has been published in over 250 scientific publications, and his world-renowned research has provided new insight into genetic and environmental causes of lung cancer, enabling novel lung cancer therapies. Currently, Dr. Wong continues his investigative pursuits, in to developing novel therapeutic strategies for small cell and non-small cell lung cancer. He received both his PhD and MD from Columbia University, completed his residency at Massachusetts General Hospital, and was a fellow at the Dana-Farber Cancer Institute.

Dr. Eder is the Clinical Director of the Early Drug Development Program, performing Phase I clinical trials of new cancer medicines.  He was previously the Clinical Director of the Experimental Therapeutics Program for the Dana-Farber/Harvard Cancer Center and had responsibility for the trials performed at the DF/HCC. These clinical and basic research activities have involved collaboration with clinical and basic scientists at Harvard and elsewhere, the Cancer Therapy Evaluation Program of the National Cancer Institute, presentations at national and international meetings, and correspondence with a number of leaders in the field of cancer drug development.

Dr. Richardson is Corman professor of Medicine at Harvard medical School and serves as Clinical Program Leader and Director of Clinical Research of the Jerome Lipper Multiple Myeloma Center and has led several novel, biologically-derived translational efforts in multiple myeloma.  He holds numerous advisory board positions and is a member of dozens of professional organizations. In addition, he has published hundreds of original papers, reviews, chapters, and monographs in many leading peer-reviewed publications including The New England Journal of Medicine, Blood, and Journal of Clinical Oncology and many othersDr. Richardson has led the study and clinical development of numerous novel drugs in the treatment of multiple myeloma which have contributed to improvement in outcome for patients.

Dr. Weichselbaum is the Daniel Ludwig Professor and Founding Chairman of the Department of Radiation and Cellular Oncology at the University of Chicago.  He is also the Director of Ludwig Center for Metastasis Research.  He is a founder of GenVec (NASDAQ), Convergence Therapeutics (acquired by ILEX/Genzyme)and Catherex, a Herpes Virus Gene Therapy Company.  Dr. Weichselbaum sits on the Scientific Advisory Board of Reflexion-a radiotherapy imaging company.  He has over 550 publications in peer-reviewed journals and is an Editor of the textbook “Cancer Medicine”.  He is a member of the Institute of Medicine of the National Academy of Sciences.

Dr. Kharbanda received his Ph.D in cell biology in 1986 from the All India Institute of Medical Sciences (AIIMS), New Delhi. He joined the Dana-Farber Cancer Institute, Harvard Medical School in 1986 as a Research Fellow and undertook extensive research work in the area of oncology drug discovery and development. In 1991, he was promoted to Assistant Professor at Harvard Medical School where he worked as a faculty member for 15 years. Dr. Kharbanda is a co-author on more than 180 papers published in peer-reviewed scientific journals and holds > 20 patents and patent applications in the area of oncology drug discovery. In 2000, he joined Ilex Oncology Inc., as Vice-President & head of R&D, where his responsibilities included development of novel drugs for cancer. Dr. Kharbanda was a member of the team which successfully advanced three oncology drug candidates to human clinical trials. Following the acquisition of Ilex Oncology by Genzyme Corporation, Dr. Kharbanda founded multiple companies in the oncology space including Linus Oncology, NanoProteagen and Genus Oncology, where he is co-founder and Chief Scientific Officer.